The present invention relates to a process suitable for adoption to large scale manufacture of 1-isopropyl-3-5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate of formula (I), which is a selective 5-HT4 receptor ligand intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson's and Schizophrenia.
本发明涉及一种适用于大规模生产式(I)的 1-异丙基-3-5-[1-(
3-甲氧基丙基)
哌啶-4-基]-[1,3,4]恶二唑-2-基}-1H-
吲唑草酸盐的工艺、这是一种选择性 5-HT4 受体
配体,用于对症治疗阿尔茨海默病以及其他记忆和认知障碍,如注意力缺陷多动症、帕
金森病和精神分裂症。